Kazia Therapeutics company info

What does Kazia Therapeutics do?
Kazia Therapeutics ADR (ASX:KZA), (NASDAQ:KZIA) is an innovative biotechnology company focused on the development of novel treatments for cancer. Traded on the NASDAQ under the symbol KZIA, the company's portfolio includes projects aimed at addressing some of the most challenging forms of the disease, such as glioblastoma, the most common and aggressive form of brain cancer. Kazia's primary objective is to advance these treatments through clinical trials with the goal of improving patient outcomes and providing new hope to individuals and families affected by cancer. Through collaboration with leading cancer research institutions and a dedication to scientific excellence, Kazia strives to translate cutting-edge research into therapies that can make a real difference in the fight against cancer.
Kazia Therapeutics  company media
Company Snapshot

Is Kazia Therapeutics a public or private company?

key
Ownership
Public

How many people does Kazia Therapeutics employ?

people
Employees
9

What sector is Kazia Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Kazia Therapeutics ?

location pin
Head Office
New South Wales, Australia

What year was Kazia Therapeutics founded?

founded flag
Year Founded
1994
What does Kazia Therapeutics specialise in?
/Cancer Therapies /Drug Development /Clinical Trials /Pharmaceutical Research /Oncology Treatments /Glioblastoma Medication

What are the products and/or services of Kazia Therapeutics ?

Overview of Kazia Therapeutics offerings
Paxalisib, a PI3K inhibitor designed for treating glioblastoma, a form of brain cancer.
EVT801, an anti-cancer compound targeting VEGFR3 for various solid tumors.
Collaboration on using paxalisib in combination therapies for enhanced treatment efficacy in brain cancer.
Research partnership focused on developing targeted therapies for pediatric brain cancers.
Initiatives on improving drug delivery systems for better penetration of therapeutics into the brain.
Investigation into novel biomarkers for more precise treatment targeting in oncology

Who is in the executive team of Kazia Therapeutics ?

Kazia Therapeutics leadership team
  • Dr. John Edwin Friend II, M.D.
    Dr. John Edwin Friend II, M.D.
    CEO, MD & Director
  • Ms. Gabrielle  Heaton BBUS (ACC), CPA
    Ms. Gabrielle Heaton BBUS (ACC), CPA
    Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer
  • Ms. Anna  Sandham
    Ms. Anna Sandham
    Company Secretary